Accéder au contenu
Merck
  • Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost/benefit decision-making tasks.

Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost/benefit decision-making tasks.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2014-10-21)
Jay G Hosking, Stan B Floresco, Catharine A Winstanley
RÉSUMÉ

Successful decision making often requires weighing a given option's costs against its associated benefits, an ability that appears perturbed in virtually every severe mental illness. Animal models of such cost/benefit decision making overwhelmingly implicate mesolimbic dopamine in our willingness to exert effort for a larger reward. Until recently, however, animal models have invariably manipulated the degree of physical effort, whereas human studies of effort have primarily relied on cognitive costs. Dopamine's relationship to cognitive effort has not been directly examined, nor has the relationship between individuals' willingness to expend mental versus physical effort. It is therefore unclear whether willingness to work hard in one domain corresponds to willingness in the other. Here we utilize a rat cognitive effort task (rCET), wherein animals can choose to allocate greater visuospatial attention for a greater reward, and a previously established physical effort-discounting task (EDT) to examine dopaminergic and noradrenergic contributions to effort. The dopamine antagonists eticlopride and SCH23390 each decreased willingness to exert physical effort on the EDT; these drugs had no effect on willingness to exert mental effort for the rCET. Preference for the high effort option correlated across the two tasks, although this effect was transient. These results suggest that dopamine is only minimally involved in cost/benefit decision making with cognitive effort costs. The constructs of mental and physical effort may therefore comprise overlapping, but distinct, circuitry, and therapeutic interventions that prove efficacious in one effort domain may not be beneficial in another.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide chlorhydrique, ACS reagent, 37%
Sigma-Aldrich
Acide chlorhydrique, ACS reagent, 37%
Sigma-Aldrich
Chlorure d'hydrogène solution, 4.0 M in dioxane
Sigma-Aldrich
Acide chlorhydrique solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Acide chlorhydrique, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
Acide chlorhydrique, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
Chlorure d'hydrogène solution, 2.0 M in diethyl ether
Sigma-Aldrich
Acide chlorhydrique, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Supelco
Acide chlorhydrique solution, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Chlorure d'hydrogène solution, 1.0 M in diethyl ether
Sigma-Aldrich
Hydrogen chloride, ReagentPlus®, ≥99%
Sigma-Aldrich
Acide chlorhydrique solution, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
Chlorure d'hydrogène solution, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Acide chlorhydrique solution, 32 wt. % in H2O, FCC
Sigma-Aldrich
Yohimbine hydrochloride, ≥98% (HPLC), powder
Sigma-Aldrich
Chlorure d'hydrogène solution, 1.0 M in acetic acid
Supelco
Hydrogen chloride – methanol solution, ~1.25 m HCl (T), for GC derivatization, LiChropur
Supelco
Hydrogen chloride – ethanol solution, ~1.25 M HCl, for GC derivatization, LiChropur
Supelco
Hydrogen chloride – 2-propanol solution, ~1.25 M HCl (T), for GC derivatization, LiChropur
Yohimbine hydrochloride, European Pharmacopoeia (EP) Reference Standard